Physician profile
Puneet Bhalla
NPI 1336115542
$9,619.05
in general payments reported to CMS, 2019-2025
64 companies · $2,206 in 2025
The $2,206 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $817 · 2020: $670 · 2021: $1,187 · 2022: $2,077 · 2023: $1,117 · 2024: $1,544 · 2025: $2,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,866.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $1,104.97 | 2020-2025 | Reblozyl, Opdivo, Opdualag |
| Abbvie INC. | $710.89 | 2019-2025 | Epkinly, Venclexta |
| Pfizer INC. | $628.74 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $623.09 | 2020-2025 | Enhertu, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $527.73 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Janssen Biotech, INC. | $518.80 | 2019-2025 | Darzalex, Tecvayli, Rybrevant |
| Merck Sharp & Dohme LLC | $409.83 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Genentech USA, INC. | $392.43 | 2019-2025 | Polivy, Alecensa, Tecentriq |
| Novartis Pharmaceuticals Corporation | $331.97 | 2019-2025 | |
| Exelixis INC. | $294.22 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $288.05 | 2020-2025 | Rezlidhia, Tavalisse, Gavreto |
| Pharmacyclics LLC, An Abbvie Company | $249.63 | 2019-2023 | Imbruvica, Epkinly |
| Daiichi Sankyo INC. | $242.87 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Genzyme Corporation | $215.11 | 2019-2025 | |
| Eisai INC. | $207.00 | 2019-2025 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Puneet Bhalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.